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Abstract
The perihydroxylated perylene quinone hypericin has been reported to possess potent anti-metastatic and antiangiogenic
activities, generated by targeting diverse crossroads of cancer-promoting processes via unique mechanisms. Hypericin is the
only known exogenous reagent that can induce forced poly-ubiquitination and accelerated degradation of heat shock
protein 90 (Hsp90) in cancer cells. Hsp90 client proteins are thereby destabilized and rapidly degraded. Hsp70 client
proteins may potentially be also affected via preventing formation of hsp90-hsp70 intermediate complexes. We show here
that hypericin also induces enhanced degradation of hypoxia-inducible factor 1a (HIF-1a) in two human tumor cell lines,
U87-MG glioblastoma and RCC-C2VHL2/2 renal cell carcinoma and in the non-malignant ARPE19 retinal pigment epithelial
cell line. The hypericin-accelerated turnover of HIF-1a, the regulatory precursor of the HIF-1 transcription factor which
promotes hypoxic stress and angiogenic responses, overcomes the physiologic HIF-1a protein stabilization which occurs in
hypoxic cells. The hypericin effect also eliminates the high HIF-1a levels expressed constitutively in the von-Hippel Lindau
protein (pVHL)-deficient RCC-C2VHL2/2 renal cell carcinoma cell line. Unlike the normal ubiquitin-proteasome pathway-
dependent turnover of HIF-a proteins which occurs in normoxia, the hypericin-induced HIF-1a catabolism can occur
independently of cellular oxygen levels or pVHL-promoted ubiquitin ligation of HIF-1a. It is mediated by lysosomal
cathepsin-B enzymes with cathepsin-B activity being optimized in the cells through hypericin-mediated reduction in
intracellular pH. Our findings suggest that hypericin may potentially be useful in preventing growth of tumors in which HIF-
1a plays pivotal roles, and in pVHL ablated tumor cells such as renal cell carcinoma through elimination of elevated HIF-1a
contents in these cells, scaling down the excessive angiogenesis which characterizes these tumors.
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Introduction
Formation of tumor metastases by disseminating cancer cells
and their explosive growth remains the most prevalent cause for
cancer treatment failure and death. Tumor cells remodel the
extracellular matrix, modify cell adhesion properties, invade
surrounding tissues and transmigrate to distal organs to form
metastatic foci. Developing foci generate hypoxia and a need for
neoangiogenesis to support growth. Hypoxia stabilizes the stress
response precursor HIF-1a [1], leading to its translocation to the
nucleus via an hsp90 dependent process [2,3] and heterodimer-
ization with HIF-1b, generating the functional HIF-1 transcription
factor. HIF-1 promotes transcription of ,100 stress response
target proteins including VEGF. VEGF stimulates increased
expression of its primary receptor VEGFR2. The VEGF-
VEGFR2 complexes which form require association with hsp90
to activate the downstream signaling that initiates the neoangio-
genic cascade, [4] and activates the integrin-focal adhesion kinase
(FAK)-Src signaling complex. Both FAK and Src are also hsp90
client proteins, requiring association with this chaperone for
maintaining their functional conformations [5,6]. These functions
include formation of focal adhesions associated with an F-actin
contractile apparatus that are linked to the cell membrane and
activate the migration machinery via interaction with the
extracellular matrix [7]. Thus, Hsp90 inhibition can disrupt
several sites in angiogenic and cell dispersion signaling cascades
and interfere with tumor progression.
The marked increases in HIF-1a content that occur in many
tumor types implicate HIF-1 in promoting oncogenesis. Tumor
progression is accelerated via heterogeneous mechanisms includ-
ing dysfunctional/deleted VHL gene in renal cell carcinoma and
hemangioblastoma [8], inactivated IDH1 gene in glioblastoma
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paraganglioma, and others [10]. Indeed, elevated intratumoral
HIF-1a (or HIF-2a) are associated with accelerated patient
mortality, evident from retrospective immunohistochemical anal-
yses of paraffin embedded biopsy sections from various tumors
[11]. It is currently accepted that diminishing tumoral HIF-1a
levels may encompass important clinical benefits, spurring
intensive searches for small molecule inhibitors of HIF-1a.
Reagents with diverse activities capable of interfering with
tumor cell proliferation, migration and neoangiogenic signaling
are likely to more effectively inhibit formation of metastases and
benefit cancer patients. One such potentially promising reagent is
the perihydroxylated perylene quinone - hypericin. We found that
hypericin effectively inhibits formation of metastases by murine
breast and squamous cell carcinoma tumors in vivo [12], apparently
by interfering with signaling pathways that promote angiogenesis
[13] and tumor cell proliferation [14]. The common denominator
linking these different activities is a unique ability of hypericin to
act as exogenous inducer of forced poly-ubiquitination of heat
shock protein 90 (Hsp90), destabilizing and rapidly degrading a
plethora of hsp90-client proteins [14].
Here we report that hypericin can degrade HIF-1a in cells via a
unique hypoxia and proteasome independent mechanism. Al-
though HIF-1a is an hsp90 client protein [15] degraded by other
hsp90 inhibitors [16], the hypericin-induced HIF-1a catabolism
appears to involve a unique lysosomal cathepsin-B dependent
mechanism, activated in a reduced intracellular pH environment.
We also show that the angiogenic signaling cascade can be affected
by hypericin at multiple sites, rendering this molecule potentially
promising in anti cancer therapy.
Results
Forced HIF-1a degradation under hypoxia by cell
treatment with hypericin
Aiming to decipher the mechanism for the anti-angiogenic
activity of hypericin [13], we examined whether hypericin affects
HIF-1a adaptive stabilization, which occurs under hypoxia in the
absence of proline and asparagine hydroxylation [1] in three
human cell lines: U87-MG glioblastoma cells, RCC-C2
VHL2/2
(C2
VHL2/2) renal carcinoma cells deficient in pVHL, and ARPE-
19 retinal pigment epithelial cells. The cells were first exposed to
hypericin for 72 hrs, the time required for optimal hypericin
effects to develop and hypoxia generated chemically with CoCl2
and with a low oxygen atmosphere (0.5% O2,5 %C O 2 and 94.5%
N2) for the last 6 hours of treatment to prevent hypoxic
cytotoxicity. HIF-1a levels were analyzed in cytosolic and nuclear
fractions by Western blots. The results, Fig. 1 show that exposure
to 10 mM and 30 mM of hypericin effectively reduced the hypoxia-
induced increases in HIF-1a levels in a hypericin dose dependent
manner in ARPE-19 cells (Fig. 1A) and in U87-MG cells (Fig. 1B).
Reductions in HIF-1a were more pronounced in the nuclear
fractions of both cell lines, particularly when hypoxia was induced
chemically with CoCl2.
To determine how hypericin enhances HIF-1a degradation we
used the VHL gene-deleted C2
VHL2/2 cell line. pVHL, the
substrate recognition and binding module of an E-3 ubiquitin
ligase complex binds HIF-1a following prolyl hydroxylation on the
HIF-1a prolyl-hydroxylase domain protein-2 [17], thereby
ubiquitinating HIF-1a and mediating the proteasomal degrada-
tion of this stress-response transcription factor precursor [18].
pVHL deficiency disrupts this oxygen-dependent degradation
response, leading to constitutive accumulation of HIF-1a.W e
examined the HIF-1a content in C2
VHL2/2 cells following 72 hr
treatments with hypericin. The constitutively high HIF-1a content
in C2
VHL2/2 cells decreased following exposure to hypericin
(Fig. 1C exhibits) in a manner similar to the reductions in HIF-1a
observed in U87-MG and ARPE-19 cells treated with hypericin
under hypoxia. HIF-1a elimination by hypericin in C2
VHL2/2
cells occurred independently of pVHL and was found to be
insensitive to inhibition with MG132 or ALLN proteasomal
calpain inhibitors (Fig. 1C), thus excluding involvement of the
ubiquitin-proteasome pathway in this process. HIF-1a degrada-
tion by hypericin was, however effectively inhibited by the
cathepsin-B inhibitor CA-074 in C2
VHL2/2 cells (Fig. 1C) and
unaffected by CLi-III, a cathepsin-L inhibitor (data not shown).
These observations indicate that the hypericin-enhanced HIF-1a
turnover is mediated through catabolism by a cathepsin-B type
enzyme independently of the ubiquitin-proteasome pathway.
Stable transfection of VHL into C2
VHL2/2 cells restored the E3
ubiquitin ligase complex functionality [19], including HIF-1a
proteasomal degradation under normoxia and HIF-1a stabiliza-
tion under hypoxic conditions (Fig. 1D). In this setting hypericin
also accelerated HIF-1a degradation under hypoxia, abrogating
the hypoxia-induced HIF-1a stabilization in VHL-reconstituted
RCC-C2
VHL+ cells (C2
VHL+ cells) (Fig. 1D). HIF-1a degradation
by hypericin in C2
VHL+ cells was also inhibited by CA-074
(Fig. 1D). Thus, the cathepsin-B pathway remains the major route
of HIF-1a degradation by hypericin under hypoxia following
pVHL reconstitution.
Hypericin elicits reductions in intracellular pH
The shift in HIF-1a turnover from the physiologic pVHL-
mediated proteasomal degradation to a cathepsin-B dependent
mechanism caused by hypericin prompted us to investigate
whether changes in intracellular conditions contributed to this
shift. Since light-induced photodynamic activities of hypericin
elicit reductions in the intracellular pH (pHi) of tumor cell [20], we
hypothesized that hypericin can also cause intracellular pH
reduction in the dark via redox activities, optimizing conditions
for lysosomal enzyme activity. pHi was measured in U87-MG and
C2
VHL2/2 cells treated with 10, and 30 mM hypericin for 72 hrs
in the dark, monitoring pH dependent esterolytic cleavage of the
acetoxymethyl-ester derivative of BCECF (please see Methods for
details). Despite strict maintenance of dark conditions, we
recorded hypericin concentration dependent reductions in intra-
cellular pH in U87-MG and C2
VHL2/2 cells (Fig. 1E). The
cytosolic pHi decreased in U87-MG cells from a baseline of
7.1260.08 to 6.7560.06 with 10 mM of hypericin (p#0.05), and
to 6.4560.20 with 30 mM hypericin (p#0.03). In C2
VHL2/2 cells
the pHi declined from 7.1860.04 to 6.8560.28 (p#0.08) with
10 mM hypericin and to 6.4260.2 with 30 mM hypericin
(p#0.05). These studies show that hypericin also elicits concen-
tration dependent reductions of cellular pHi in the dark.
To determine whether reduced pHi is essential for cathepsin-B
mediated HIF-1a degradation by hypericin, effect of cytoplasmic
alkalinization with NH4Cl on HIF-1a cytosolic content was
examined in hypericin-treated cells. U87-MG cells were exposed
to hypericin for 72 hrs in the dark and 150 mM CoCl2 hypoxia
induced during the last 6 hrs of incubation in media supplemented
with 20 mM ammonium chloride to elicit cytoplasmic alkaliniza-
tion. Cytosolic extracts were prepared and Western blots
developed with antibody to HIF-1a. Fig. 1F shows that prevention
of intracellular pH reduction diminished HIF-1a degradation by
hypericin, however at the higher 30 mM hypericin concentration
some HIF-1a degradation under hypoxia did take place. This
degradation appeared to be less sensitive to the cathepsin-B
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PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e22849Figure 1. Enhancement of HIF-1a turnover under hypoxic conditions in cells exposed to hypericin. [A] ARPE19, [B] U87-MG, [C] RCC-
C2
VHL2/2 and [D]. RCC-C2
VHL+ (VHL gene reconstituted) cell lines were exposed to 10 and 30 mM hypericin for 72 hrs. The cultures were subjected to
hypoxic conditions with 150 mM CoCl2 (A & B, upper panel doublets) and with a low oxygen atmosphere (0.5% O2, 94.5% N2 and 5% CO2)( A&B ,
lower panel doublets) for the last 6 hours of treatment. Hypericin caused degradation of HIF-1a. The mediator of HIF-1a proteolytic cleavage was
characterized by inhibition of HIF-1a degradation with the CA-074 cathepsin B inhibitor, with MG-132 and with ALLN proteasomal calpain inhibitors,
administered to the cultures for the last 6 hours of incubation with the cells. Cytosolic extracts and nuclear extracts were prepared, separated on SDS-
PAGE and Western blots developed with anti-HIF-1a. Equal loading was confirmed with b-Actin. [E]. Effects of hypericin on the intracellular pH of U87-
MG and C2
VHL2/2 cells. Quantitative BCECF, pH-dependent fluorescence was measured spectrofluorimetrically (FRU denotes Fluorescence Relative
Units). [F]. Analysis of the role of hypericin-mediated intracellular pH reduction in promoting HIF-1a turnover under CoCl2 hypoxia, determined
following cytoplasmic alkalinization with 20 mM NH4Cl applied during the last 6 hrs of incubation. Cytoplasmic alkalinization diminished the
hypericin-induced HIF-1a turnover under CoCl2 hypoxia.
doi:10.1371/journal.pone.0022849.g001
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pathway dependent mechanism.
Hypericin interferes with HIF-1a binding to VEGF and
GLUT1 gene promoter HRE sequences
The hypericin enhanced HIF-1a degradation and consequent
HIF-1 nuclear content deficiency, were hypothesized to diminish
HIF-1 interactions with hypoxia response elements (HREs) on
stress response gene promoters as VEGF and GLUT1. HIF-1
binding to human VEGF gene promoter HRE was, therefore
analyzed in hypericin-treated U87-MG, C2
VHL2/2 and ARPE-19
cells using Fluorescence Electromobility Shift Assays (F-EMSA).
Cells were exposed to hypericin for 72 hrs, nuclear extracts
prepared and DNA-protein complex formation with VEGF
promoter HRE element-containing fluorescent probes were
analyzed for SYPRO Ruby Fluorescence. In C2
VHL2/2 cells
bearing high baseline HIF-1 content, HIF-1 formed DNA-protein
complexes with the HRE probe (Fig. 2A). No free probe was
detected (SYBER Green staining, left panel), reflecting a mostly
bound DNA probe. Upon treatment with 30 mM hypericin, HIF-
1-HRE complex formation was markedly decreased with most
DNA probe remaining unbound (lane 2).
In normoxic U87-MG cells, HIF-1-HRE complex levels were
low and increased under hypoxia leaving no detectable free DNA
Figure 2. Interactions of HIF-1 with hypoxia response elements (HREs). Found on promoters of: [A]. The VEGF gene, analyzed by
Fluorescence Electromobility Shift Assay (F-EMSA). Nuclear proteins were separated on 6% SDS-PAGE, stained with SYBER Green labeled DNA probe
and unbound protein detected with SYPRO Ruby protein binding fluorochrome. Gels were scanned using FL-5000 laser-based scanner. [B]. The
GLUT1 gene analyzed by chromatin immunoprecipitation (ChIP). Sheared chromatin was immunoprecipitated with anti HIF-1a antibody and DNA
isolated from this chromatin was amplified with primers specific for the GLUT1 gene promoter region. [C]. Interference by hypericin with VEGF
promoter activation in tumor cell lines. Left figure - C2
VHL2/2 cells. Lane 1 – untreated cells, lane 2 cells treated with 30 mM hypericin for 72 hrs. Right
figure - U87-MG cells. Lane 1 – untreated cells, lane 2 – cells subjected to hypoxia (150 mM CoCl2 for last 6 hrs), lane 3 - CoCl2-hypoxia for last 6 hrs
and hypericin 30 mM for 72 hrs, and lane 4 - hypericin, 30 mM for 72 hrs.
doi:10.1371/journal.pone.0022849.g002
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abrogated by hypericin cell treatment (Fig. 2A, middle panel)
leaving the DNA probe mostly unbound. In hypoxic ARPE-19
cells protein-HRE complex levels were higher compared to
normoxic baselines and hypericin effectively reduced HIF-1 -
probe binding. Similarly, free probe levels low in hypoxic cells,
increased following exposure to hypericin (Fig. 2A, right panel).
Treatment with hypericin of cell lines with high HIF-1 levels due
to hypoxia or defective pVHL (C2
VHL2/2 cells) resulted in
reduced interactions with hypoxia response elements.
HIF-1 interactions with other stress response gene-promoter
HREs as the GLUT1 gene were also affected by hypericin as
shown by chromatin immunoprecipitation analyses. Chromatin
prepared from nuclei of hypericin-treated and control cells was
sheared and HIF-1 containing fragments immunoprecipitated
with anti-HIF-1 antibody. HRE-bound HIF-1 levels were
determined from amplification of extracted DNA by PCR using
GLUT1 promoter specific probes. In U87-MG cells exposure to
hypoxia resulted in increased HIF-1 interactions with GLUT1
promoter HRE (Fig. 2B middle panel), whereas concomitant
exposure to hypericin reduced the amounts of promoter bound
HIF-1 (lane 3). Similar reductions occurred in ARPE19 cells
(Fig. 2B, left panel). In C2
VHL2/2 cells, hypericin caused dramatic
declines in GLUT1 promoter-bound HIF-1 (Fig. 2B, right panel).
Overall, the reductions in HIF-1a cytoplasmic contents in
hypericin-treated hypoxic cells also resulted in reduced mature
HIF-1 transcription-promoting activities in the cell nuclei,
diminishing HIF-1 interactions with the VEGF and GLUT1 gene
promoters.
Hypericin interferes with VEGF promoter activation in
tumor cell lines
The decreases in HIF-1 binding to VEGF and GLUT1
promoters caused by hypericin, prompted analyses of the effects
of hypericin on VEGF promoter activation. U87-MG and
C2
VHL2/2 cells were transiently transfected with a reporter
construct, containing the HRE element of VEGF-A gene
(pGL3P-1100). The cells were split into 30 mM hypericin treated
group (for 72 hrs) and untreated control group. Luciferase activity
was measured against the pGL3P vehicle control vector transfected
cells devoid of the reporter construct. Fig. 2C (left exhibit) shows
expressionofhighluciferaseactivityinuntreatedcontrolC2
VHL2/2
transfectant cells, which showed a trend towards suppressed
luciferase activity in hypericin-treated C2
VHL2/2 cells by approx-
imately 40%, suggesting that hypericin tends to interfere with
VEGF promoter activation in C2
VHL2/2 cells, however the
differences did not reach statistical significance (P=0.06, Mann
Whitney test). Luciferase levels of vehicle plasmid pGL3P were low
and similar in both groups (not shown).
In U87-MG cells, the VEGF promoter was also strongly
activated in response to hypoxia (Fig. 2C), whereas cell treatment
with 30 mM hypericin completely abolished the hypoxia-induced
promoter activation (P=0.05) (3
rd column). Hypericin alone
without hypoxia had no effect on promoter activation (4
th
column). pGL3P vehicle control vector transfectants were low in
all groups (not shown). Thus, hypericin can inhibit VEGF-
promoter activation under hypoxic conditions via HIF-1a
degradation in U87-MG cells.
Hypericin modulates VEGF gene transcription in tumor
cell lines
The downregulation of VEGF promoter activation due to
hypericin-induced HIF-1a catabolism in hypoxic cells prompted
investigation of the effects of the hypericin-elicited, HIF-1a
catabolism on VEGF gene transcription. U87-MG and ARPE-
19 cells exposed to hypericin (72 hrs in the dark) were subjected to
CoCl2 hypoxia for the last 6 treatment hours. RNA was prepared
and VEGF transcription analyzed by semi-quantitative RT-PCR
using primers spanning exon1 and exon8 of VEGF-A gene. These
primers amplify all six VEGF splice variants and the semiquan-
titative analyses enable differential profile analyses of levels of each
VEGF splice transcript. The results show that in ARPE-19 cells,
hypoxia induced modulations in VEGF splice variant transcrip-
tional profiles. When hypoxia was combined with exposure to
hypericin, transcription of VEGF189 and VEGF165 isoforms which
dramatically increased under hypoxia declined (Fig. 3A), partic-
ularly with the 30 mM dose (Fig. 3A, lane 4). VEGF145 expressed
in untreated control cells and suppressed under hypoxia was re-
expressed following hypericin treatment (Fig. 3A, lane 4).
In U87-MG cells baseline levels of some VEGF isoforms under
normoxia, mainly VEGF189 were high due to hypoxia-indepen-
dent mechanisms as reactive oxygen species [21], NO [22],
phosphatidylinositol-3-kinase and MAP kinase activation through
the action of mTOR [23], or loss of IDH1 gene function in
glioblastoma [9]. Nevertheless transcription of VEGF isoforms
primarily VEGF206, VEGF165 and VEGF121 increased following
cell exposure to hypoxia. Their transcription decreased after cell
exposure to 30 mM hypericin (Fig. 3B, lane 3). In C2
VHL2/2 cells
Figure 3. Modulation of expression patterns of the different VEGF-A splice variants by cell treatment with hypericin. A. In ARPE-19
cells, B. in U87-MG cells and C. in C2
VHL2/2 cells.
doi:10.1371/journal.pone.0022849.g003
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quently very high at baseline. Exposure to hypericin (72 hrs)
induced reductions in VEGF206, VEGF189 and marginally also
VEGF165 (Fig. 3C). Interestingly, when hypericin-treated cells
were also exposed to CA-074 (100 mg/ml), the cathepsin-B
inhibitor which prevented the hypericin-enhanced HIF-1a
degradation, VEGF gene transcription was also stimulated
compared to cells treated with hypericin only (Fig. 3C). In
summary, hypericin stimulated changes in VEGF splice variant
expression patterns most notably in ARPE-19 cells (Fig. 3A) and
also detectable in U87-MG and C2
VHL2/2 cells.
Prevention of VEGFR2/KDR expression in hypericin
treated cells
The modulations in VEGF gene transcription patterns induced
by hypericin-mediated accelerated HIF-1a degradation, warrant-
ed analyses of hypericin effects on mediators of angiogenesis at the
protein level. Possible correlations with Hsp90 activities were also
evaluated due to hsp90 polyubiquitination, inactivation and
degradation which are also induced by hypericin [14], and the
roles hsp90 plays in key sites of the angiogenic cascade [2,24].
Effects of hypericin treatment on VEGFR2/KDR expression
were examined in the three cell lines, including ARPE-19 because
VEGFR2 is also expressed on RPE cells [25]. The treatment with
hypericin induced marked suppression of VEGFR2 cellular content
in U87-MG and ARPE-19 cells however, receptor levels were
unaffected in renal C2
VHL2/2 cells (Fig. 4A). To determine if
reduced VEGFR2 expression resulted from diminished VEGF
production we supplemented the growth medium of U87-MG and
ARPE-19 cells with VEGF (10 ng/ml) with or without heparin (1
unit/ml for 48 hrs) one day after hypericin administration and
analyzed VEGFR2 expression in these cells. These treatments did
not modify the hypericin downregulated VEGFR2 expression and
did not increase VEGFR2 levels (data not shown). We therefore,
examined whether hypericin modulated VEGFR2 mRNA expres-
sion levels in these cells. RNA was prepared from hypericin treated
cells (72 hrs in the dark) and semiquantitative RT-PCR analyses
performed with VEGFR2-specific primers, using VEGFR1 as
comparative reference. These experiments revealed that VEGFR2
gene transcription was effectively and selectively inhibited by
hypericin in all three cell lines, whereas VEGFR1 transcription was
less affected (Figure S1). They suggest that hypericin triggers
epigenetic effects selectively downregulating expression of VEGFR2
and several additional genes. However this large topic exceeds the
scope of this manuscript and will be further discussed elsewhere.
VEGFR2 downstream signaling following activation by VEGF-
VEGFR2 interactions also requires association with hsp90 [24].
Hsp90 involvement is relevant to our analyses of antiangiogenic
effects, because we previously reported in murine breast and
squamous carcinoma tumor cells that hypericin induces hsp90
polyubiquitination and accelerated degradation, destabilizing and
degrading hsp90-client proteins in these cells [14]. VEGFR2
downstream signaling activates alphavbeta3 and focal adhesion
kinase (FAK) to form cytoskeletal focal adhesions and F-actin
polymers [24]. FAK and Src are also hsp90 client proteins and
indeed hypericin treatment interferes with F-actin polymerization
(Fig. 4B). We therefore investigated the hypericin effects on
VEGFR2 association with hsp90, analyzing VEGFR2 pull down
following immunoprecipitation with anti-hsp90 antibody. Fig. 4C
shows that VEGFR2 co-immunoprecipitates with hsp90, however
this co-immunoprecipitation was abrogated following treatment
with 30 mM hypericin in all three cell lines. This apparently
universal finding indicates that VEGF-VEGFR2-Hsp90 complex
formation diminishes due to actions of hypericin.
We also confirm here that hypericin induces hsp90 polyubiqui-
tination in human cell lines. Immunoprecipitation of U87-MG
and C2
VHL2/2 cell lysates with anti-hsp90 pulled down ubiquitin
following hypericin exposure and vice versa: immunoprecipation
with anti-ubiquitin pulled down hsp90 (Fig. 4D).
Hsp90 poly-ubiquitination interferes with the nuclear
transport of HIF-1a prior to degradation of HIF-1a
To determine whether the hypericin-mediated destabilization of
HIF-1a also depends on the hypericin-induced poly-ubiquitination
of hsp90 we performed time dependent evaluations of the effects of
Figure 4. Effects of hypericin on complex formations between
VEGFR2, Hsp90 and on HOP-hsp70 intermediate complexes.
[A]. Western blot analyses of VEGFR2 protein levels in cytosolic extracts
from untreated control cells (C), or cells treated with 30 mM hypericin
for 72 hrs (HYP). [B]. Staining of U87-MG cells with Phalloidin-FITC. (1)
Untreated cells and (2) cells treated with hypericin 30 mM for 72 hrs.
Orange arrows show F-actin filaments; yellow arrows depict collapsed
actin globules following exposure to hypericin. [C]. VEGFR2-hsp90
complex formation following treatment with hypericin 30 mM for
72 hrs. Results of immunoprecipitation with anti-Hsp90 antibody and
development of Western blots with anti-VEGFR2 antibody. Hypericin
diminished VEGFR2-Hsp90 complex formation. [D]. Induction of forced
hsp90 poly-ubiquitination by hypericin (30 mM for 72 hrs) in human
cancerous cell lines. Top panel – immunoprecipitation with anti-hsp90
and Western blot with anti-hsp90 antibody (control); middle panel -
immunoprecipitation with anti-hsp90 and Western blot with anti-
ubiquitin, and lower panel immunoprecipitation with anti-ubiquitin and
Western blot with anti-hsp90. (I.P – immunoprecipitation; W.B. –
Western blots).
doi:10.1371/journal.pone.0022849.g004
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hsp90-associated HIF-1a cellular contents in U87-MG cells under
hypoxia. The cells were exposed to 10 and 30 mM of hypericin for
48 hrs at which time hsp90 poly-ubiquitination became detectable
and for 72 hrs when the chaperone has been degraded [14].
Hypoxia was induced with CoCl2 for the last 6 hours of the
experiment, the cells lysed and both cytosolic and nuclear extracts
were prepared. Hsp90 was immunoprecipitated with its corre-
sponding antibody and Western blots developed with anti-HIF-1a
antibodies to monitor for hsp-90 bound HIF-1a and with anti-
hsp90 as control (Fig. 5A). HIF-1a levels bound to hsp90 were
compared with total HIF-1a analyzed on Western blots directly
from whole cytosolic and nuclear fractions. The results show that
following exposure to hypericin for 48 hrs hsp90 became poly-
ubiquitinated, yet chaperone degradation was primarily noted at
the higher dose of 30 mM hypericin (Fig. 5A, left image). Cytosolic
HIF-1a began to be degraded at the 48 hr time point, only after
treatment with 30 mM hypericin (Fig. 5B, upper left panel).
However, HIF-1a nuclear transport was most strongly abrogated
by both hypericin dose levels (Fig. 5B, 48 hr time-point 2
nd panel,
nuclear fraction). This was due to the high dependence of HIF-1a
nuclear transport on intact hsp90 chaperone activity [26]. Hsp90
poly-ubiquitination by hypericin caused loss of chaperone activity
and prevented the physiologic HIF-1a trans-migration into the
nucleus where it normally dissociates from hsp90 [27]. HIF-1a
bound to hsp90 and co-immunoprecipitated with anti hsp90
antibody was also more strongly degraded due to hsp90
ubiquitination after 48 hrs (Fig. 5B, lower left panel). At 72 hrs
cytosolic hsp90 was highly degraded to below detection level
(Fig. 5A, right image) and affected both the co-immunoprecipi-
tated HIF-1a and HIF-1a transported into the nucleus (Fig. 5B,
third and forth images). The total cytosolic HIF-1a content at the
Figure 5. Effects of hypericin-mediated hsp90 poly-ubiquitination on the destabilization of HIF-1a in U87-MG cells under hypoxia.
U87-MG cells were exposed to 10 & 30 mM hypericin for 48 hrs (left panels) and 72 hrs (right panels) under hypoxic conditions (150 mM CoCl2) and
hsp90 expression and chaperone activities were analyzed. Cytosolic extracts were immunoprecipitated with anti-hsp90 and Western blots developed
with: [A] anti-hsp90 antibodies. [B] anti HIF-1a. (lower panel), which analyzed hsp90-bound HIF-1a levels. Bound HIF-1a levels were compared to total
HIF-1a obtained from Western blots performed on whole cytosolic (left panels) and nuclear extracts (right panels). (HYP denotes hypericin). [C].
Sensitivity of hypericin-induced poly-ubiquitinated Hsp90 to proteasome and cathepsin B inhibitors in U87-MG cells. Left panel – MG132 proteasome
inhibitor and right panel CA-074, cathepsin B inhibitor. [D]. Effects of cell treatment with hypericin on formation of Hop co-chaperone-mediated
hsp90-hsp70 intermediate complexes. Analyses of Hop content in these complexes: left pair refers to U87-MG cells and right pair to ARPE19 cells.
doi:10.1371/journal.pone.0022849.g005
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protein remained detectable. Thus, cytosolic HIF-1a associated
with hsp90 decreased as poly-ubiquitination of hsp90 increased
(Fig. 5A & 5B) but correlated less with the actual hsp90
degradation.
We hypothesized that these differences may be due to the
disparity in mechanisms of hsp90 and HIF-1a degradation in
hypericin treated cells: hsp90 via the ubiquitin-proteasome
pathway and HIF-1a via cathepsin B (Fig. 1C). Since hypericin
modulates the intracellular pHi (Fig. 1E) and the intracellular pHi
affects HIF-1a degradation (Fig. 1F), we also examined whether
turnover of ubiquitinated hsp90 under reduced intracellular pH
conditions is mediated by the proteasome or is also affected by
cathepsin B. U87-MG cells exposed to hypericin (72 hrs), were
subjected to hypoxia, to the MG132 proteasome inhibitor and to
CA-074, the cathepsin B inhibitor for the last 6 hrs of the
experiments and effects on hsp90 levels were monitored. Fig. 5C,
left panel shows that presence of MG132 prevented hsp90
degradation pointing to a major role for the proteasome in
hypericin-induced, poly-ubiquitinated hsp90 degradation, howev-
er, unlike HIF-1a, hsp90 remained unaffected by CA-074 (Fig. 5C,
right panel). Although HIF-1a is tightly bound by hsp90 in the cell
cytosol, the two dissociate following hsp90 ubiquitination and
undergo degradation via different cellular protein turnover
pathways.
The ubiquitination of hsp90 by hypericin also affects activities of
hsp70 chaperones. Intermediate complexes these two chaperones
form are regulated by a cohort of co-chaperones, enabling hsp90
to affect hsp70 client proteins that together regulate folding of
large numbers of cellular proteins. We examined possible
implications of hsp90 ubiquitination by hypericin on Hsp70/
Hsp90 intermediate complex formation, by analyzing cell contents
of the important stress-inducible protein 1 (STI1) co-chaperone
known as the ‘‘Hsp70/Hsp90 Organizing Protein’’ (HOP). HOP
associates with both Hsp70 and Hsp90, thereby regulating their
activities [28]. Fig. 5D shows that destabilizing hsp90 by hypericin
abrogated hsp90-Hop intermediate complex formations, prevent-
ing their co-immunoprecipitation. Furthermore, the hsp90
inactivation and degradation caused dramatic decreases in Hop
cellular contents. Similar observations were reported in human
colon carcinoma cells in which HOP levels correlated with those of
hsp90 [29]. These findings indicate that hsp90 poly-ubiquitination
and chaperone inactivation caused by treatment of human
tumorigenic cell lines with hypericin also eliminate VEGF-
VEGFR2-Hsp90 complex formation as well as Hsp70-Hsp90-
HOP intermediate complexes in cancerous cells.
Discussion
One example for a multi-targeting molecule which can inhibit
tumorigenesis [30], angiogenesis [13] and development of
metastases [12], is hypericin. To exert this anticancer activity
array, hypericin must affect several key processes at crossroads
controlling multiple cell signaling pathways. Our initial studies
identified hsp90 as one major hypericin target, being the sole
exogenous reagent known to selectively bind to and induce forced
hsp90 poly-ubiquitination [14]. Hsp90 poly-ubiquitination is
disparate from the negative regulatory hsp90 mono-ubiquitination
which follows hsp90 hyper-acetylation due to suppressed HDAC6
activity [31]. HDAC6 has hsp90 among its target substrates [32–
33]. Unlike this reversible mono-ubiquitination, hypericin-forced
hsp90 poly-ubiquitination accelerates degradation of this chaper-
one causing loss of its activities [14]. Hsp90 client proteins, many
with signaling kinase activities, are consequently destabilized and
rapidly degraded, generating deficiencies in key signaling media-
tors compromising pathways vital for angiogenesis, cell migration
and invasion. We initially observed this phenomenon in murine
tumor cells [14] and confirm here its occurrence in human brain
and kidney cancer cell lines (Fig. 4D). We also show here that
hsp90 poly-ubiquitinated by the effects of hypericin is degraded in
the proteasome (Fig. 5C). Vital co-chaperones as HOP are
additional targets that become degraded following hsp90 poly-
ubiquitination, potentially affecting hsp70 client proteins as well.
The stress-response transcription factor precursor HIF-1a is
another key signaling regulator shown here to be targeted by
hypericin for accelerated degradation. HIF-1a also depends on
hsp90 for stability and maturation into HIF-1 and is degraded by
geldanamycin derivatives [34]. The hallmark of the HIF-1a
response to stress and hypoxia includes HIF-1a protein stabiliza-
tion [17,35], its activation and nuclear translocation. These are
abrogated by hypericin which triggers accelerated HIF-1a
degradation via a unique mechanism which is independent of
cellular oxygen levels. Hypericin is photodynamic, possessing
unique electron accepting and donating properties that enable
action as both oxidizing and reducing agent [36]. Electrochemical
and electron paramagnetic resonance studies suggest that its redox
potential in physiological pH (E1/V=21.01 mEV) is moderately
lower than those of cellular bioenergized electron transfer reaction
mediators. Thus, hypericin can scavenge electrons to propel its
redox activities within cells in the dark [37].
The hypericin-enhanced HIF-1a degradation which follows the
poly-ubiquitination of hsp90 and loss of activity of this chaperone,
overcomes the hypoxic HIF-1a stabilization generated either by
CoCl2 chemical hypoxia or by a low oxygen atmosphere (Figs. 1A
& 1B). It can, therefore occur in cells in which normal oxygen-
dependent HIF-1a degradation is disrupted as the VHL deleted
C2
VHL2/2 cells (Fig. 1C). The resulting high constitutive HIF-1a
intracellular accumulation generates highly vascularized tumors as
renal cell carcinoma or hemangioblastoma. The degradation of
HIF-1a in C2
VHL2/2 cells with hypericin reverses the high
constitutive HIF-1a cellular accumulations in manners that are
independent of the proteasome and unaffected by its inhibitors, yet
sensitive to CA-074, a cathepsin-B inhibitor. Sensitivity to CA-074
also characterizes other tumor cell lines indicating preference for
cathepsin-B in hypericin mediated HIF-1a turnover. Cathepsin-B
activity may be optimized by hypericin-mediated reductions in
intracellular pHi. Hypericin is known to cause light-dependent
photodynamic intracellular pHi reductions [20]; it is shown here
that pHi reductions also occur in the dark via the redox reactivities
of hypericin. Under these conditions the hypericin-induced poly-
ubiquitination of hsp90 disrupts the binding of hsp90 to client
proteins as HIF-1a and accelerates the degradation of both hsp90
and HIF-1a, however hsp90 turnover occurs in the proteasome
(Fig. 5C) whereas HIF-1a is degraded by cathepsin B (Fig. 1C).
The effects on HIF-1a classify hypericin among HIF-1a
degradation-enhancing agents as the HDAC inhibitor Trichosta-
tin A [38] and 17-Allylaminogeldanamycin (17-AAG) [34],
although the mechanism of the hypericin action may be different.
Nevertheless, since hsp90 is required for HIF-1a transport into the
cell nucleus [2], hsp90 inactivation by hypericin may also
accelerate HIF-1a degradation similarly to 17-AAG [15]. Indeed,
hypericin also interferes with HIF-1a migration into the cell
nucleus preventing its heterodimerization into a mature transcrip-
tion factor by creating deficiency in HIF-1a cytosolic content and
by inactivating hsp90 required for HIF-1a nuclear migration.
Consequently, HIF-1 binding to stress-response gene promoter
HRE elements diminishes, suppressing their trans-activation and
gene expression (Fig. 2).
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tory effects by cell treatment with hypericin, which future studies
should address. These were evident in the highly effective
downregulated expression of the VEGFR2 gene in all the three
cell lines that were evaluated in this study, demonstrated in Figure
S1. Interestingly, gene expression profiling studies revealed
epigenetic modulations of gene expression patterns induced by
another hsp90 inhibitor, the benzoquinone ansamycin, geldana-
mycin analogue, 17-AAG [43], which is also a HIF-1a
degradation-enhancing agent [34].
The hypericin-induced HIF-1a degradation is likely to attribute
important clinical utilizations to hypericin in management of
pathological consequences of excessive responses to stress.
Targeting HIF-1a for degradation is currently a vital option in
anti-cancer therapy to inhibit tumor neoangiogenesis and glucose
transport. Our findings suggest that such activities can be
countered by hypericin.
Indeed, a Phase I/II clinical trial testing hypericin in patients
with recurrent progressive glioblastoma multiforme (grade IV) and
anaplastic astrocytoma (grade III) who failed other therapies, has
been completed in 6 North American Medical Centers with
promising outcomes. 7/35 GBM patients were objective respond-
ers (20%) with a median survival of 6 months, despite this difficult
patient group. [44]. It should encourage further evaluation of
hypericin in brain tumors and other cancer types in which high
HIF-1a levels cause clinical exacerbation.
Materials and Methods
Preparation of hypericin
Hypericin (10,11-dimethyl-1,3,4,6,8,13 hexahydroxy naphtho-
dianthrone) was synthesized from emodin according to a method
developed by Y. Mazur. Emodin was converted to emodin
anthrone by reflux in SnCl2
.2H2O in HOAc, followed by reflux in
concentrated HCl. The pellet was filtered, water-washed and dried
at 40–50uC under vacuum to yield emodin anthrone. Self
condensation of emodin anthrone to protohypericin was achieved
by dissolving emodin anthrone in pyridine and heating with
piperidine, pyridine-N-oxide and catalytic amounts of FeSO4
(Sigma-Aldrich Chemicals). This resulted in the formation of
protohypericin.
Photoactivated ring closure of protohypericin to form hypericin
was achieved by irradiation of protohypericin with visible light to
yield free hypericin which was crystallized from pyridine resulting
in a hypericin-pyridine complex. This complex was heated to
160uC for 2 hrs in high vacuum. The resulting free hypericin was
dissolved in methanol and converted to a hypericin-monosodium
salt by adding aqueous NaHCO3, precipitation with hexane and
crystallization from methanol. Hypericin was purified to 98.7% by
chromatographies on silica gel (Merck 60; 70–230 mesh) and
eluted with methanol:EtOAc 2:1 and 1% aqueous NaH2PO4. For
the bioassays hypericin was dissolved to 4 mM in 70% aqueous
ethanol. Subsequent dilutions were made in culture media limiting
the final concentration of EtOH to #1%.
Since hypericin is a potent photosensitizer all studies were conducted
in strict darkness (ambient light maintained ,300 mW/cm
2).
Cell lines and culture conditions
ARPE-19, a non-malignant human retinal pigment epithelial
cell line, which expresses functional VEGF receptors [39] and
U87-MG human glioblastoma cell line were obtained from the
American Type Culture Collection. RCC2
VHL2/2 human renal
cell carcinoma cell line (VHL locus deleted) was a gift from Dr. W.
Marston Linehan, NIH.
ARPE-19 cells were cultured in 1:1 DMEM/F-12 nutrient
medium, U87-MG and RCC-C2
VHL2/2 in DMEM. All media
were supplemented with 10% FBS, L-glutamine (2 mM), penicillin
100 U/ml and streptomycin 100 mg/ml (GibcoBRL, Paisley,
Scotland).
Chemicals
29,79-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxyme-
thyl ester (BCECF), CoCl2, MG-132 and CA-074 were purchased
from Sigma-Calbiochem (Darmstadt, Germany). N-Acetyl-Leu-Leu-
Nle-CHO (ALLN) was from BIOMOL International LP.
Hypoxia
Hypoxia was induced chemically using CoCl2 (150 mM),
administered for the last 6 hrs of experiments and incubated in
37uC, 5% CO2 incubator for 6 hrs. In some experiments hypoxia
was also generated by forming a low oxygen atmosphere of 94.5%
N2,5 %C O 2 and 0.5% O2.
Preparation of nuclear and cytosolic cellular fractions
Nuclear and cytosolic extracts were prepared from U87-MG,
RCC
VHL2/2 and ARPE-19 cells. The cells were washed twice with
PBS and swollen for 15 minutes on ice with buffer A consisting of
10 mM Hepes pH 7.9, 10 mM KCl, 1 mM EDTA, 1 mM EGTA,
1 mM DTT and complete protease inhibitor cocktail 40 mg/ml
(RocheMolecularBiochemicals,Mannheim,Germany).NP-40was
then added to a concentration of 0.5% for induction of cell lysis and
the nuclei sedimented by centrifugation at 14,000 g for 15 minutes
at4uC.Thesupernatantswerecollectedforuse ascytosolicfractions
and stored at 270uC. Nuclear extracts were prepared by dissolution
of nuclei in Buffer C containing 20 mM Hepes pH 7.9, 500 mM
KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT and complete
Protease Inhibitor Cocktail, 40 mg/ml at 4uC for 15 minutes
following centrifugation at 14,000 g for 10 minutes at 4uC. The
purity of the cytosolic and nuclear fractions which were obtained
using this method is demonstrated in Figure S2, which shows
Western blots (left image) and Coomassie blue staining (right image)
ofcytosolicfractions (left 4 lanes)andnuclearfractions (right4 lanes)
separated on the same SDS-polyacryl-amide gels.
Immunoprecipitation, Western Blot analyses
Cells were lysed in 10 mM HEPES pH 7.9, 10 mM KCl,
1 mM EDTA, 1 mM EGTA, 1 mM DTT buffer and 40 mg/ml
Complete Protease Inhibitor mix (from Boehringer Mannheim,
Germany). Immunoprecipitates were prepared using rabbit
polyclonal anti-ubiquitin, anti-HIF-1a, anti-VEGFR2, anti-
Hsp90 and anti-GAPDH antibodies (Santa Cruz Biotechnology,
CA). Immune complexes were immobilized on protein A/G
agarose beads (Santa Cruz, USA) and separated by SDS PAGE.
Western blots were prepared using semi-dry transfer to nitrocel-
lulose membranes following standard procedures, stained with
peroxidase-tagged secondary antibodies and developed for chemi-
luminescence (SuperSignalH West Pico, Pierce, Rockford IL USA).
Chromatin immunoprecipitation (ChIP)
DNA from 10
7 cells/plate in 100 mm culture dishes was
crosslinked to proteins with 1% formaldehyde in media for
10 min. Cells were washed 62 with cold PBS containing 1 mM
PMSF, 1 mg/ml aprotinin and 1 mg/ml pepstatin A, lysed in
200 ml SDS lysis buffer (1% SDS, 10 mM EDTA 40 mg/ml
protease inhibitors mix, 50 mM Tris pH 8.1) and subjected to 5–
10 sonication rounds (30 sec pulses at medium intensity). Cell
debris were removed by centrifugation, the supernatants diluted
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1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1 and 167 mM NaCl),
incubated overnight (4uC) with anti HIF-1a antibody and with
salmon sperm DNA/protein A-agarose to reduce non-specific
background. Pellets were washed with low salt, high salt buffer
series (LiCl buffer and TRIS-EDTA [TE] buffer). DNA/protein
complexes were eluted with 1% SDS, 0.1 M NaHCO3. DNA-
protein crosslinks were reversed with 5 M NaCl at 65uC
overnight. Immunoprecipitated DNA segments were purified with
High Pure PCR Product Purification Kit; (Roche Diagnostics,
Mannheim, Germany) and amplified by PCR using primers
spanning the DNA binding sites of the immunoprecipitated
protein. DNA fragments containing the HRE found on the human
VEGF-A promoter were amplified using the primers:
F- 59-CAGGAACAAGGGCCTCTGTCT-39 and R- 59–
GCACTGTGGAGTCTGGCAAA–39
Intracellular pH measurements
Intracellular pH (pHi) was measured as pH-dependent decreas-
es in fluorescence emission intensity of 29,79-bis-(2-carboxyethyl)-
5-(and-6)-carboxy-fluorescein (BCECF), accumulating in cells
following esterolytic cleavage of acetoxymethyl-ester derivative of
BCECF (29,79-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein
acetoxymethyl ester) by cellular esterases [40]. Fluorescence was
measured using an Ascent Fluoroscan (ThermoLabsystems). Cells,
5610
4/well in 96 well flat bottom microplates were administered
with hypericin and incubated for72 hrs in the dark. The growth
medium was removed, the cells loaded with 0.33 or 1 mM
BCECF-AM in PBS for 30 minutes at 37uC and unincorporated
dye washed with PBS. Intracellular BCECF was excited at 506/
460 nm and fluorescence emission measured at 485 nm. pHi
calibration to convert fluorescence intensity into pH values was
achieved using the nigericin-K
+ method, following exposure to
high K
+ buffer (140 mM KCl, 1.2 mM MgSO4, 1.2 mM
KH2PO4, 1.3 mM CaCl2, 12.0 mM D-glucose, 10 mM HEPES,
pH 6.0, pH 7.0 and pH 8.0 in the presence of 20 mM nigericin, a
H
+/K
+ exchanger [41]. Cytoplasmic alkalinization to neutralize
hypericin-induced reductions in intracellular pH was achieved by
cell exposure to 20 mM NH4Cl [42].
RT-PCR analyses
RNA was extracted in Trizol (Invitrogen, USA), washed with
isopropanol and with ethanol air dried and dissolved in DEPC
ddH2O. RNA content was calibrated spectrophotometrically and
stored at 270uC. RNA OD280/OD260$1.5 was used for
amplification and semiquantitative RT-PCR analyses, performed
using ReddyMix Reverse-iT kit (ABgene, UK).
Specific primers were designed from GeneBank
TM sequences
using the Primer3 Software (Whitehead Institute., USA) or derived
from the literature. Amplified cDNAs were subjected to electro-
phoresis in 2% agarose gels containing 100 ng/ml ethidium
bromide and photographed under UV light-induced fluorescence.
VEGF primers spanning Exon1 and Exon8 used were:
(F) 59-TGCCTTGCTGCTCTACCTCC-39),
(R) 59- TCACCGCCTCGGCTTGTCAC-39)
GLUT1 promoter region (SLC2A1 gene) (NM-006516):
(F) 59–CTTCACTGTCGTGTCGCTGT–39,
(R) 59–TGAAGAGTTCAGCCACGATG–39
VEGFR2
(F) 59–GTGACCAACATGGAGTCGTG–39,
(R) 59–TGCTTCACAGAAGACCATGC–39
VEGFR1
(F) 59–GGCTCTGTGGAAAGTTCAGC–39
(R) 59–GCTCACACTGCTCATCCAAA–39
b-Actin
(F) 59–CATTGCTCCTCCTGAGCG–39,
(R) 59–CAACCGACTGCTGTCACC–39.
Transient transfection and luciferase reporter assay
Transient transfections of luciferase reporter plasmid pGL3-1100
containing the VEGF gene promoter HRE, driven by the SV-40
promoter (a gift from Dr. Casey C. Case, Sangamo Biosciences,
Richmond, CA) were performed using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). Empty pGL3 vector was used as mock
transfection control (also obtained from Dr. Casey C. Case).
Transfection efficiency was evaluated by co-tranfecting the two
vectors with pGFP (green fluorescence protein plasmid) (and percent
transfected cells monitored). Luciferase activity was evaluated using
the Dual-Luciferase Reporter assay system (Promega, Madison WI)
according to the manufacturer’s instructions.
Fluorescence electromobility shift assays (F-EMSA)
Nuclear extracts were prepared from test cells, calibrated and
stored at 270uC. Samples were mixed with a DNA probe
complementary to HRE sequences in binding buffer (750 mM
KCl, 0.5 mM DTT, 0.5 mM EDTA, 50 mM Tris pH 7.4) for
15 min at 2uC. Samples were separated on 6% non-denaturing
polyacrylamide gels by electrophoresis. Gels were stained with
SYBER Green EMSA stain (which binds and stains DNA),
(Molecular Probes, USA) for 20 min with gentle agitation followed
by 26washing with dH2O. DNA was visualized using FLA-5000
laser-based scanner, (Fujifilm Corp. USA) with filter which excites
at 450 nm (or 488 nm) and emits at 520 nm. Thereafter, gels were
stained with SYPRO Ruby EMSA stain for 3 hrs in the dark,
(which binds and labels proteins), (Molecular Probes, USA),
washed 26in dH2O and scanned in laser-based FL5000 scanner
using SYPRO Ruby filters (emission at 610 nm according to
manufacturer’s protocol).
Supporting Information
Figure S1 Selective downregulation of VEGFR2 gene
expression by hypericin compared to VEGFR1. RNA was
prepared from the human cell lines, ARPE19, U87-MG and
C2
VHL2/2 after treatment with hypericin (72 hrs in the dark) and
VEGFR2 mRNA expression was monitored compared to that of
VEGFR1. Left lane untreated control cells, right lane treatment
with hypericin (30 mM). Top panel VEGFR2 gene, middle panel
VEGFR1 gene, bottom panel b-Actin housekeeping gene. Semi-
quantitative RT-PCR analyses. Hypericin induced strong down-
regulation of VEGFR2 gene transcription to below detection levels
of the assay in all three cell lines. The effect was specificto VEGFR2
whereas VEGFR1 transcription was only marginally reduced in
U87-MG and C2
VHL2/2 cells and unaffected in ARPE19 cells.
(TIF)
Figure S2 Comparisons of the protein profiles of
cytosolic preparations with those of nuclear extracts
prepared from the same cells. Figure is presented for the sole
purpose of validating the purity of each cellular fraction in
preparations derived from U87-MG GBM cells (left exhibit) and
RCC2
VHL2/2 cells (right exhibit, Coomassie blue staining).
(TIF)
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